<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114319</url>
  </required_header>
  <id_info>
    <org_study_id>CTNO155X2101</org_study_id>
    <secondary_id>2016-001861-10</secondary_id>
    <nct_id>NCT03114319</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first in human (FIH) trial is to characterize the safety and tolerability
      of the SHP2 inhibitor TNO155 and identify a recommended dose for future studies in adult
      patients with advanced solid tumors in selected indications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has been designed as a Phase I, open-label, dose finding study with a dose
      escalation part and a dose expansion part in adult patients with selected advanced solid
      tumors. The study treatment, TNO155, will be taken until the patient experiences unacceptable
      toxicity, progressive disease and/or treatment is discontinued at the discretion of the
      investigator or the patient or due to withdrawal of consent. Some patients will be
      participating in a food effect investigation as an exploratory objective.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2017</start_date>
  <completion_date type="Anticipated">March 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 3 years; at least once per treatment cycle</time_frame>
    <description>All patients participating in this study will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms, cardiac imaging and ophthalmological assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities</measure>
    <time_frame>up to 28-day cycle</time_frame>
    <description>Incidence and nature of dose limiting toxicities (DLTs) in the dose escalation part. A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle (either 21 days or 28 days, depending on the cohort's treatment schedule) with TNO155</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>30 months</time_frame>
    <description>Area under the plasma concentration time curve of TNO155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>From start of treatment for 34 months</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of TNO155, e.g., overall response rate per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pERK</measure>
    <time_frame>At screening and between Cycle 1 and Cycle 3 on treatment for 30 months</time_frame>
    <description>On treatment versus baseline comparison of pharmacodynamic markers e.g., pERK (Phosphorylated form of Extracellular signal-regulated kinase) on newly obtained tumor samples by IHC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>30 months</time_frame>
    <description>highest observed plasma concentration of TNO155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>30 months</time_frame>
    <description>Time of highest observed plasma concentration of TNO155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent terminal elimination half-life</measure>
    <time_frame>30 months</time_frame>
    <description>terminal elimination half-life of TNO155</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Patients With Advanced EGFR-mutant Non-smallcell Lung Cancer</condition>
  <condition>Head-and-Neck Squamous Cell Cancer, RAS/RAF Wild-type Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>TNO155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNO155 for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNO155</intervention_name>
    <description>TNO155 for oral administration</description>
    <arm_group_label>TNO155</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to understand and voluntarily sign the ICF and able to comply with the study
             visit schedule and the other protocol requirements.

          2. Patient (male or female) ≥18 years of age willing to agree to not father a
             child/become pregnant and comply with effective contraception criteria.

          3. Must have progressed following standard therapy, or for whom, in the opinion of the
             Investigator, no effective standard therapy exists, is tolerated or is appropriate.

          4. ECOG (Eastern cooperative oncology group) performance status ≤2

        Exclusion Criteria:

          1. Tumors harboring known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations.

          2. History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO.

          3. Any medical condition that would, in the investigator's judgment, prevent the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          4. Clinically significant cardiac disease.

          5. Active diarrhea or inflammatory bowel disease

          6. Insufficient bone marrow function

          7. Insufficient hepatic and renal function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>trialandresults.registries@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Meyers</last_name>
      <phone>617-643-1820</phone>
      <email>Betha_meyers@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murielle Georges</last_name>
      <phone>656-888-4563</phone>
      <email>georgesm@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Helena Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNO155</keyword>
  <keyword>SHP2</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>NSCLC</keyword>
  <keyword>HNSCC</keyword>
  <keyword>EGFR</keyword>
  <keyword>GIST</keyword>
  <keyword>PTPN11</keyword>
  <keyword>cancers with a mass</keyword>
  <keyword>bulky tumor</keyword>
  <keyword>nodule</keyword>
  <keyword>lump</keyword>
  <keyword>advanced solid malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

